In patients with inflammatory bowel disease(IBD), chronic inflammation is a major risk factor for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated cancer is distinct from sporad...In patients with inflammatory bowel disease(IBD), chronic inflammation is a major risk factor for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated cancer is distinct from sporadic colorectal carcinoma and the critical molecular mechanisms underlying this process have yet to be elucidated. Patients with IBD have also been shown to be at increased risk of developing extra-intestinal malignancies. Medical therapies that diminish the mucosal inflammatory response represent the foundation of treatment in IBD, and recent evidence supports their introduction earlier in the disease course. However, therapies that alter the immune system, often used for long durations, may also promote carcinogenesis. As the population of patients with IBD grows older, with longer duration of chronic inflammation and longer exposure to immunosuppression, there is an increasing risk of cancer development. Many of these patients will require cancer treatment, including chemotherapy, radiation, hormonal therapy, and surgery. Many patients will require further treatment for their IBD. This review seeks to explore the characteristics and risks of cancer in patients with IBD, and to evaluate the limited data on patients with IBD and cancer, including management of IBD after a diagnosis of cancer, the effects of cancer treatment on IBD, and the effect of IBD and medications for IBD on cancer outcomes.展开更多
Mannose-binding lectin (MBL), a mammalian lectin, is a pattern recognition molecule of the innate immune system and recognizes carbo-hydrates that are exposed on pathogens. In this study, we observed that fructose dow...Mannose-binding lectin (MBL), a mammalian lectin, is a pattern recognition molecule of the innate immune system and recognizes carbo-hydrates that are exposed on pathogens. In this study, we observed that fructose down regu-lates MBL-mediated innate immune mechanisms against both influenza A virus (IAV) and Staphy-lococcus aureus. These mechanisms include the lectin complement pathway and coagulation enzyme-like activities on both pathogens. Fur-thermore, fructose also reduces MBL-mediated phagocytosis of S. aureus and IAV and MBL- mediated IAV infection to epithelial cells. In contrast, sucrose inhibits MBL-mediated im-mune mechanisms against S. aureus but not IAV. Together, our studies show that dietary sugars, in particular fructose, negatively regulate the innate immunity against viral and bacterial pathogens.展开更多
文摘In patients with inflammatory bowel disease(IBD), chronic inflammation is a major risk factor for the development of gastrointestinal malignancies. The pathogenesis of colitis-associated cancer is distinct from sporadic colorectal carcinoma and the critical molecular mechanisms underlying this process have yet to be elucidated. Patients with IBD have also been shown to be at increased risk of developing extra-intestinal malignancies. Medical therapies that diminish the mucosal inflammatory response represent the foundation of treatment in IBD, and recent evidence supports their introduction earlier in the disease course. However, therapies that alter the immune system, often used for long durations, may also promote carcinogenesis. As the population of patients with IBD grows older, with longer duration of chronic inflammation and longer exposure to immunosuppression, there is an increasing risk of cancer development. Many of these patients will require cancer treatment, including chemotherapy, radiation, hormonal therapy, and surgery. Many patients will require further treatment for their IBD. This review seeks to explore the characteristics and risks of cancer in patients with IBD, and to evaluate the limited data on patients with IBD and cancer, including management of IBD after a diagnosis of cancer, the effects of cancer treatment on IBD, and the effect of IBD and medications for IBD on cancer outcomes.
文摘Mannose-binding lectin (MBL), a mammalian lectin, is a pattern recognition molecule of the innate immune system and recognizes carbo-hydrates that are exposed on pathogens. In this study, we observed that fructose down regu-lates MBL-mediated innate immune mechanisms against both influenza A virus (IAV) and Staphy-lococcus aureus. These mechanisms include the lectin complement pathway and coagulation enzyme-like activities on both pathogens. Fur-thermore, fructose also reduces MBL-mediated phagocytosis of S. aureus and IAV and MBL- mediated IAV infection to epithelial cells. In contrast, sucrose inhibits MBL-mediated im-mune mechanisms against S. aureus but not IAV. Together, our studies show that dietary sugars, in particular fructose, negatively regulate the innate immunity against viral and bacterial pathogens.
